Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > LinkedIn

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Feb 27, 2023 3:00pm

54 Views

Post# 35307846

RE:RE:RE:LinkedIn

Anything to show a factual basis to get to breakeven and see sales grow to $90 on picked up interest is a path to the $1.50-$2.00 range and encouraging. If the new formulations get them to $100m+ forecast by fall/winter, it's a path to $3.00 and that's what they need to get to and show they can do. Anything else is a freebie at this point. Just get the financial plan set.

<< Previous

Bullboard Posts

Next >>

The Market Online’s Weekly Cannabis Report – July 5, 2024